Furthermore, the authors demonstrated a novel mode of action of stenothricin using BioMAP antimicrobial profiles and cytological profiling. The successful identification of biosynthetic gene clusters for unreported molecules described herein highlights the importance of developing a global approach to interrogate the biosynthetic capacities of microorganisms.
The 2015 winner of the JA Medal for reviews is for an insightful review on new cycles of antibiotic discovery and development, entitled 'Prospects for new antibiotics: a molecule-centered perspective' authored by Christopher T. Walsh and Timothy A. Wencewicz. 2 Unlike general encyclopedic overviews for research and development of new drugs, this thoughtful paper was particularly focused on how new chemical scaffolds and new bacterial targets could be identified and what existing targets should be re-examined for fulfilling current clinical needs.
The review begins with a description of the author's personal pathway to antibiotic research, where D-fluoroalanine was identified as a suicide substrate for alanine racemase essential for peptidoglycan assembly, and replacement of the D-Ala-D-Ala termini of the muramyl pentapeptide intermediate with D-Ala-D-Lactate was shown as the mechanism underlying vancomycin resistance in pathogenic vancomycin-resistant enterococci. The emergence of antibiotic resistance is inevitable, as the origin of the resistance genes in pathogenic bacteria derives from intrinsically resistant microbes in nature. Therefore, there is always a need for the next generation of antibiotics, but the success rate dropped rapidly after the short golden age of antibiotic discovery from nature and subsequent golden half century of medicinal chemistry. Furthermore, there has not been a new antibiotic scaffold for Gram-negative pathogens such as Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter species. The authors point out the importance of starting with molecular frameworks that can stand up to the rigor of development. Unfortunately, however, most antibiotic development groups and companies have chosen to reduce risk by working on known scaffolds and known targets.
The paper presents a number of promising new approaches to new scaffolds, that is, repurposing of a library built for eukaryotic kinase projects to identify hits against bacterial ATP-dependent enzymes, antisense or small interfering RNA screens that make bacterial growth sensitive to a compound that inhibits a particular pathway by lowering levels of gene expression, exploration of new niches for antibiotic-producing microorganisms such as abysses in the sea, turning on expression of silent biosynthetic gene clusters and introduction of e-DNA containing gene clusters of secondary metabolites into the generic host strain. More importantly, the authors discuss the promise of revisiting unexplored targets persisting in clinically validated antibacterial targets/pathways and of conducting combination therapy based on real-time diagnostics of the pathogen population in patients. This review provides profound insights into strategies for antibiotic discovery with new frameworks that are required for the fight against drug-resistant pathogens and as such is a worthy recipient of the 2015 JA Medal for reviews.
secondary metabolites that are involved in microbe-microbe and microbe-host interactions and demonstrated its potential to steer new platforms for therapeutic discovery. After graduation, she joined Prof. David Relman's group at Stanford University as a Life Science Research Foundation fellow to look for metabolic factors that are involved in human microbiome to gain molecular insights into how microbiota affect human diseases or health states. Currently, she works at Bayer Biologics, where she leads a metabolomics team to characterize new biological products for crop protection and crop efficiency. Dr. Liu also works in a project team together with representatives from the Pharmaceutical and Crop Science divisions of Bayer on the implementation of a comprehensive metabolomics knowledge platform.
